Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)

Next Previous
X
Search
Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS- BREAST CANCER)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abemaciclib (Primary) ; Atezolizumab (Primary) ; Everolimus (Primary) ; Giredestrant (Primary) ; Inavolisib (Primary) ; Ipatasertib (Primary) ; Pertuzumab/trastuzumab (Primary) ; Ribociclib (Primary) ; Samuraciclib (Primary)
  • Indications Advanced breast cancer; HER2 positive breast cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms MORPHEUS BC
  • Sponsors Roche

    • Most Recent Events

    • 04 Jun 2024 Interim results assessing safety and efficacy were presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
    • 24 Oct 2023 Interim results (n=32; As of 17 May 2022) assessing the efficacy of giredestrant plus ipatasertib in patients with ER+, HER2-negative, locally advanced/metastatic breast cancer, presented at the 48th European Society for Medical Oncology Congress.
    • 06 Jun 2023 Interim results at week 16 presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top